Avid wins commercial manufacturing project from Roivant

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/BrianAJackson)
(Image: iStock/BrianAJackson)
Avid Bioservices has been selected to manufacture a commercial drug substance for Enzyvant, a subsidiary of Roivant Sciences, which is developing a therapy to treat Farber disease.

As part of the deal, announced today, Avid will manufacture Enzyvant’s RVT-801, a recombinant human acid ceramidase (rhAC) enzyme replacement therapy that the company is developing as a potential treatment for Farber disease.

Enzyvant is currently conducting preclinical studies and has been granted orphan drug designation for RVT-801 in the US and EU.

According to the companies, technology transfer and clinical manufacturing have been ongoing since mid-2017. Avid will complete process characterization and optimization and will manufacture RVT-801 at its 42,000-square-foot biomanufacturing facility in Myford, CA.

Roger Lias, Avid CEO, told us earlier this week​ that “a number of new contractual commitments​” were to be expected after the company announced its completed transition to a dedicated contract development and manufacturing organization (CDMO).

Also this week, Avid announced the closing of a $20m follow-on offering. The funds will be used to expand its contract manufacturing business.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more